Original PRISMA consent protocol
breast cancer
BREAST CANCER
Participants in the PRISMA study were asked to consent to use their data and biomaterial for research into early detection, prognosis and treatment of breast cancer. They were further asked to consent to use their data and any residual biomaterial for ancillary studies into breast cancer; this included the possibility of genetic research. Participants could consent to (1) store their unprocessed screening mammogram and/or (2) complete an online questionnaire on breast cancer risk factors and/or (3) venous blood collection to obtain a DNA sample, blood serum and blood plasma and/or (4) collection of a saliva sample to obtain DNA. Informed consent was obtained before participation in the PRISMA study. A signed paper consent form was submitted at the screening site. The online questionnaire also began with a short consent form.